Saturday, 31 October 2026European Markets

XILAM ANIMATION And AJAX Have A High Dividend Yield And Return On Equity In The Entertainment Industry.

Loading stream...

(vianews) - xilam animation (xil.pa) is among this list of stock assets with the highest dividend rate and return on equity on the entertainment industry.

financial asset price forward dividend yield return on equity
xilam animation (xil.pa) €3.65 2.29% 1.96%
ajax (ajax.as) €10.80 0.83% 17.95%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. xilam animation (xil.pa)

2.29% forward dividend yield and 1.96% return on equity

xilam animation operates as an audiovisual production company in france and internationally. the company creates, produces, and distributes original programs for children and adults. it also broadcasts content on television; subscription video on demand streaming platforms, including netflix, disney +, amazon, and nbc universal; and advertising video on demand streaming platforms, such as youtube and facebook. in addition, the company produces animated, series, mini-series, and feature films. it owns the oggy, cockroaches, zig & sharko, chicky, oggy oggy in preschool, oggy next gen, les tales of lupin, moka, mr magoo, trico, and i lost my body brands. the company was incorporated in 1999 and is headquartered in paris, france.

earnings per share

as for profitability, xilam animation has a trailing twelve months eps of €0.08.

pe ratio

xilam animation has a trailing twelve months price to earnings ratio of 45.63. meaning, the purchaser of the share is investing €45.63 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.96%.

moving average

xilam animation's worth is way below its 50-day moving average of €16.37 and way below its 200-day moving average of €24.30.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, xilam animation's stock is considered to be overbought (>=80).

more news about xilam animation.

2. ajax (ajax.as)

0.83% forward dividend yield and 17.95% return on equity

afc ajax nv operates a football club primarily in the netherlands. it also operates a stadium and an youth academy. the company was founded in 1900 and is based in amsterdam, the netherlands.

earnings per share

as for profitability, ajax has a trailing twelve months eps of €2.13.

pe ratio

ajax has a trailing twelve months price to earnings ratio of 5.07. meaning, the purchaser of the share is investing €5.07 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.95%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on nov 21, 2023, the estimated forward annual dividend rate is 0.09 and the estimated forward annual dividend yield is 0.83%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ajax's stock is considered to be oversold (<=20).

sales growth

ajax's sales growth is 1.5% for the ongoing quarter and 1.5% for the next.

more news about ajax.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com